After having hosted Intellia Therapeutics (NTLA)’ CEO John Leonard at the firm’s healthcare conference, JPMorgan said management “shed light” on the thinking behind the strategic announcement made last week and also addressed the key investor inbound on the market opportunities for nex-z in transthyretin amyloidosis and ‘2002 in hereditary angioedema. The analyst, who notes that the respective pivotal studies in those indications are “progressing as planned,” keeps an Overweight rating on Intellia shares.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics price target lowered to $40 from $60 at Oppenheimer
- Intellia Therapeutics price target lowered to $50 from $70 at BMO Capital
- Intellia Therapeutics price target lowered to $48 from $60 at Evercore ISI
- Intellia Therapeutics Restructures to Focus on Late-Stage Programs
- Intellia Therapeutics price target lowered to $60 from $70 at Wells Fargo